- Home
- BSL vs CRDF Comparison
BSL vs CRDF Comparison
Compare BSL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSL | CRDF |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.1M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BSL | CRDF |
|---|---|---|
| Price | $13.51 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 71.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.19 | $1.90 |
| 52 Week High | $14.56 | $4.99 |
Technical Indicators
Market Signals| Indicator | BSL | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 39.54 | 60.44 |
| Support Level | $13.50 | $2.61 |
| Resistance Level | $13.59 | $3.31 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 29.31 | 56.23 |
Price Performance
Historical ComparisonAbout BSL Blackstone
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.